Cargando…
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB ar...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112247/ https://www.ncbi.nlm.nih.gov/pubmed/36995219 http://dx.doi.org/10.1128/aac.00053-23 |
_version_ | 1785027590540492800 |
---|---|
author | Marzinke, Mark A. Fogel, Jessica M. Wang, Zhe Piwowar-Manning, Estelle Kofron, Ryan Moser, Amber Bhandari, Pradip Gollings, Ryann Bushman, Lane R. Weng, Lei Halvas, Elias K. Mellors, John Anderson, Peter L. Persaud, Deborah Hendrix, Craig W. McCauley, Marybeth Rinehart, Alex R. St Clair, Marty Ford, Susan L. Rooney, James F. Adeyeye, Adeola Chariyalertsak, Suwat Mayer, Kenneth Arduino, Roberto C. Cohen, Myron S. Grinsztejn, Beatriz Hanscom, Brett Landovitz, Raphael J. Eshleman, Susan H. |
author_facet | Marzinke, Mark A. Fogel, Jessica M. Wang, Zhe Piwowar-Manning, Estelle Kofron, Ryan Moser, Amber Bhandari, Pradip Gollings, Ryann Bushman, Lane R. Weng, Lei Halvas, Elias K. Mellors, John Anderson, Peter L. Persaud, Deborah Hendrix, Craig W. McCauley, Marybeth Rinehart, Alex R. St Clair, Marty Ford, Susan L. Rooney, James F. Adeyeye, Adeola Chariyalertsak, Suwat Mayer, Kenneth Arduino, Roberto C. Cohen, Myron S. Grinsztejn, Beatriz Hanscom, Brett Landovitz, Raphael J. Eshleman, Susan H. |
author_sort | Marzinke, Mark A. |
collection | PubMed |
description | HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm). This report describes 52 additional infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm). Retrospective testing included HIV testing, viral load testing, quantification of study drug concentrations, and drug resistance testing. The new CAB arm infections included 7 with CAB administration within 6 months of the first HIV-positive visit (2 with on-time injections, 3 with ≥1 delayed injection, and 2 who restarted CAB) and 11 with no recent CAB administration. Three cases had integrase strand transfer inhibitor (INSTI) resistance (2 with on-time injections and 1 who restarted CAB). Among 34 CAB infections analyzed to date, diagnosis delays and INSTI resistance were significantly more common in infections with CAB administration within 6 months of the first HIV-positive visit. This report further characterizes HIV infections in persons receiving CAB preexposure prophylaxis and helps define the impact of CAB on the detection of infection and the emergence of INSTI resistance. |
format | Online Article Text |
id | pubmed-10112247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-101122472023-04-19 Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 Marzinke, Mark A. Fogel, Jessica M. Wang, Zhe Piwowar-Manning, Estelle Kofron, Ryan Moser, Amber Bhandari, Pradip Gollings, Ryann Bushman, Lane R. Weng, Lei Halvas, Elias K. Mellors, John Anderson, Peter L. Persaud, Deborah Hendrix, Craig W. McCauley, Marybeth Rinehart, Alex R. St Clair, Marty Ford, Susan L. Rooney, James F. Adeyeye, Adeola Chariyalertsak, Suwat Mayer, Kenneth Arduino, Roberto C. Cohen, Myron S. Grinsztejn, Beatriz Hanscom, Brett Landovitz, Raphael J. Eshleman, Susan H. Antimicrob Agents Chemother Antiviral Agents HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB arm and 42 in the TDF-FTC arm). This report describes 52 additional infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm). Retrospective testing included HIV testing, viral load testing, quantification of study drug concentrations, and drug resistance testing. The new CAB arm infections included 7 with CAB administration within 6 months of the first HIV-positive visit (2 with on-time injections, 3 with ≥1 delayed injection, and 2 who restarted CAB) and 11 with no recent CAB administration. Three cases had integrase strand transfer inhibitor (INSTI) resistance (2 with on-time injections and 1 who restarted CAB). Among 34 CAB infections analyzed to date, diagnosis delays and INSTI resistance were significantly more common in infections with CAB administration within 6 months of the first HIV-positive visit. This report further characterizes HIV infections in persons receiving CAB preexposure prophylaxis and helps define the impact of CAB on the detection of infection and the emergence of INSTI resistance. American Society for Microbiology 2023-03-30 /pmc/articles/PMC10112247/ /pubmed/36995219 http://dx.doi.org/10.1128/aac.00053-23 Text en Copyright © 2023 Marzinke et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Antiviral Agents Marzinke, Mark A. Fogel, Jessica M. Wang, Zhe Piwowar-Manning, Estelle Kofron, Ryan Moser, Amber Bhandari, Pradip Gollings, Ryann Bushman, Lane R. Weng, Lei Halvas, Elias K. Mellors, John Anderson, Peter L. Persaud, Deborah Hendrix, Craig W. McCauley, Marybeth Rinehart, Alex R. St Clair, Marty Ford, Susan L. Rooney, James F. Adeyeye, Adeola Chariyalertsak, Suwat Mayer, Kenneth Arduino, Roberto C. Cohen, Myron S. Grinsztejn, Beatriz Hanscom, Brett Landovitz, Raphael J. Eshleman, Susan H. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
title | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
title_full | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
title_fullStr | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
title_full_unstemmed | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
title_short | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 |
title_sort | extended analysis of hiv infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for hiv prevention: hptn 083 |
topic | Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112247/ https://www.ncbi.nlm.nih.gov/pubmed/36995219 http://dx.doi.org/10.1128/aac.00053-23 |
work_keys_str_mv | AT marzinkemarka extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT fogeljessicam extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT wangzhe extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT piwowarmanningestelle extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT kofronryan extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT moseramber extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT bhandaripradip extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT gollingsryann extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT bushmanlaner extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT wenglei extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT halvaseliask extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT mellorsjohn extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT andersonpeterl extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT persauddeborah extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT hendrixcraigw extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT mccauleymarybeth extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT rinehartalexr extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT stclairmarty extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT fordsusanl extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT rooneyjamesf extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT adeyeyeadeola extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT chariyalertsaksuwat extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT mayerkenneth extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT arduinorobertoc extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT cohenmyrons extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT grinsztejnbeatriz extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT hanscombrett extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT landovitzraphaelj extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 AT eshlemansusanh extendedanalysisofhivinfectionincisgendermenandtransgenderwomenwhohavesexwithmenreceivinginjectablecabotegravirforhivpreventionhptn083 |